Combination therapy for chronic obstructive pulmonary disease: clinical aspects.

Area of Science:

• Pulmonary Medicine
• Pharmacology

Background:

• Anticholinergics and beta-agonists are bronchodilators used for COPD.
• Combination therapy with short-acting agents has a long history but limited efficacy.
• Current guidelines recommend long-acting bronchodilators and inhaled corticosteroids for progressive COPD.

Purpose of the Study:

• To review the efficacy and safety of combination bronchodilator therapy for COPD.
• To compare combination therapy with monotherapy and placebo.

Main Methods:

• Systematic review of studies on anticholinergic and beta-agonist combinations.
• Analysis of clinical trial data on specific drug combinations like fluticasone/salmeterol and budesonide/formoterol.

Main Results:

• Combination therapies, particularly long-acting anticholinergic with long-acting beta-agonist, improve lung function over monotherapy.
• Specific combinations (fluticasone/salmeterol, budesonide/formoterol) are superior to placebo, improving lung function, exacerbation rates, and quality of life.
• Effects on survival remain unclear, and safety and pharmacoeconomic impacts require further investigation.

Conclusions:

• Combination bronchodilator therapy offers significant benefits for COPD patients with progressive symptoms.
• While effective, further research is essential to fully understand the safety profile and economic implications of these treatments.
• The role of novel agents in COPD management warrants continued exploration.